Enhanced TCR Affinity Imparts Specificity to Reverse Transcriptase Inhibitor Resistance-Associated M...
Download
1 / 3

YV9 pentamer - PowerPoint PPT Presentation


  • 59 Views
  • Uploaded on

Enhanced TCR Affinity Imparts Specificity to Reverse Transcriptase Inhibitor Resistance-Associated Mutations. YV9 pentamer. TCR α. TCR β. High affinity YV9 Pol TCRs recognize and respond to drug escape mutations. ( Efavirenz ). IL-2. TNF α. ( Nevirapine ). (Lamivudine).

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' YV9 pentamer' - cassandra-gilbert


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Enhanced TCR Affinity Imparts Specificity to Reverse Transcriptase Inhibitor Resistance-Associated Mutations

YV9 pentamer

TCR α

TCR β


High affinity yv9 pol tcrs recognize and respond to drug escape mutations
High affinity YV9 Pol Transcriptase Inhibitor Resistance-Associated MutationsTCRs recognize and respond to drug escape mutations

(Efavirenz)

IL-2

TNFα

(Nevirapine)

(Lamivudine)


High affinity yv9 tcr can endow cd4 with effector functio n
High Affinity YV9 TCR can endow CD4 with effector functio Transcriptase Inhibitor Resistance-Associated Mutationsn

CONCLUSIONS

KT.A2.CD64.YV9

  • MHC Class I restricted haTCRTransduction of CD4 cells imparts effector-like function

  • Enhanced affinity increases breadth and sensitivity of epitope recognition to include common drug escape mutations

  • High affinity YV9 TCRs may be attractive as a potential immunotherapy agent to be used in combination with current ART chemotherapeutics

45.7%

transduced

70.8% transduced

77.2%

transduced

TNFα

Acknowledgements: A.Klattenhoff, C. Baiduc, J.L. Riley

IL-2